Pioneering a decentralized clinical study on COVID-19
Huma has partnered with the Medical Research Council Epidemiology Unit at the University of Cambridge to understand the progression of presymptomatic COVID-19 infection and build early predictive models. The study uses Huma’s platform to remotely generate data from 12,435 participants from the Fenland cohort. This builds on 15 years of existing data, and aims to create a joint analytics dataset for digital biomarker discovery.
Powering a decentralized clinical study on Atrial Fibrillation
Huma is working with Bayer, Stanford Medicine, and the Stanford Center for Digital Health to power a decentralized clinical trial for patients living with atrial fibrillation. Using Huma’s platform, research teams can remotely track participants’ medication adherence, key disease symptoms, and conduct remote consultations.
Remotely supporting Pulmonary Arterial Hypertension patients
Huma is working with Bayer to remotely support patients living with Pulmonary Arterial Hypertension (PAH). Using Huma’s BreeConnect® app, patients can provide data for their care team to monitor remotely, including their Breelib® dose intake and adherence, general health, and physical activity.